Medicine To Cure Covid-19 Will Cost This Much For Each Capsule: Dr. Reddy’s Names The Medicine: Molflu
Finally, a drug is being launched in the Indian market for the treatment of the COVID-19, when the country is stricken with the fear of the next wave induced by the omicron variant.
Dr. Reddy’s Laboratories Launching Molflu
On Tuesday, Pharma major Dr. Reddy’s Laboratories announced that they are bringing molnupiravir capsules 200 mg in the country.
This antiviral drug recently got authorisation from the central for the emergency use for COVID-19 treatment.
Further, the molnupiravir capsules will be available at Rs 35 each under the brand name Molflu.
With the recommended dose of 800 mg each strip would have 10 capsules.
It is recommended twice a day for five days.
So, the total course of 40 capsules would cost Rs 1,400.
This way, it would become the most affordable treatment option available to patients, according to Dr. Reddy’s.
Availability Of Molflu Drugs
Molflu is expected to be available from early next week in pharmacies throughout the country.
The company is keeping a particular focus on States with a high caseload of COVID-19.
Manufactured in a USFDA-approved facility, Dr. Reddy’s had made adequate capacity preparations as they wanted to ensure that it was able to help patients in need, said the company in a release.
It seems that Dr. Reddy’s is among a clutch of companies who have received emergency use authorisation last week from the Drugs Controller General of India (DCGI).
The drug maker got authorization to manufacture and market Molnupiravir capsules 200 mg for the treatment of adult patients with COVID-19, who have high risk of progression of the disease.
First Of Its Kind Collaboration
Earlier, the company and Its peers, entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply molnupiravir in India and to over 100 low and middle-income countries last year.
Basically, it is a first of its kind collaboration in the Indian pharmaceutical industry.
As part of this, Dr. Reddy’s-led consortium of pharma companies collaborated to jointly sponsor, supervise and monitor the Phase III clinical trial in India.
Moreover, they have presented its findings to the Subject Expert Committee that advised the DCGI, according to the company.